AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30709714 — intervention group
Group type: EXPERIMENTAL
Intervention: Below-median intake of dietary fiber
Number of subjects: 159
Study 30709714 — intervention group
Group type: EXPERIMENTAL
Intervention: Below-median intake of potassium
Number of subjects: 159
Study 30555484 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxic training (NO)
Number of subjects: 34
Study 30555484 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic training (HO)
Number of subjects: 34
Study 30555484 — intervention group
Group type: COMPARATOR
Intervention: Control (Normoxic vs Hypoxic)
Number of subjects: 34
Study 26110345 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 14
Study 26110345 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 14
Study 25222702 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT) with sequential 17β-estradiol plus oral progesterone
Number of subjects: 0
Study 25222702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22769858 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment group (FNB with 0.4 mL/kg 0.375% bupivacaine plus 1:200,000 epinephrine after spinal anesthesia but before the operation)
Number of subjects: 82
Study 22769858 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment group (FNB with 0.4 mL/kg 0.375% bupivacaine plus 1:200,000 epinephrine immediately after the operation)
Number of subjects: 82
Study 22769858 — intervention group
Group type: COMPARATOR
Intervention: Pre-control group (FNB with normal saline before the operation)
Number of subjects: 82
Study 22769858 — intervention group
Group type: COMPARATOR
Intervention: Post-control group (FNB with normal saline after the operation)
Number of subjects: 82
Study 22769858 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment group
Number of subjects: 82
Study 22769858 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment group
Number of subjects: 82
Study 22769858 — intervention group
Group type: COMPARATOR
Intervention: Pre-control group
Number of subjects: 82
Study 22769858 — intervention group
Group type: COMPARATOR
Intervention: Post-control group
Number of subjects: 82
Study 20538418 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg, 4 times/day
Number of subjects: 9
Study 20538418 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 200 mg, 4 times/day
Number of subjects: 9
Study 20538418 — intervention group
Group type: COMPARATOR
Intervention: Morphine 15 mg, 4 times/day
Number of subjects: 9
Study 18035292 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.2%/sufentanil 1 microg/mL (group 1)
Number of subjects: 63
Study 18035292 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.125%/sufentanil 1 microg/mL (group 2)
Number of subjects: 63
Study 18035292 — intervention group
Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.125%/sufentanil 1 microg/mL (group 3)
Number of subjects: 63
Study 16220067 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 30 mg QD
Number of subjects: 40
Study 16220067 — intervention group
Group type: COMPARATOR
Intervention: Tolvaptan 15 mg BID
Number of subjects: 40
Study 16220067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11751777 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinupristin/dalfopristin (RP59500) 7.5 mg/kg infused over 1 h twice daily for 5 days
Number of subjects: 20
Study 11751777 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinupristin/dalfopristin (RP59500)
Number of subjects: 20
Study 11751777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10363631 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate free biofiltration (AFB)
Number of subjects: 20
Study 10363631 — intervention group
Group type: COMPARATOR
Intervention: Bicarbonate hemodialysis (HD)
Number of subjects: 20
Study 8618812 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical procedures (coronary artery bypass graft, thoracic operations, cholecystectomy, inguinal hernia repair)
Number of subjects: 157
Study 8618812 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 157
Study 8618812 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical interventions (all groups except control)
Number of subjects: 157
Study 1773780 — intervention group
Group type: EXPERIMENTAL
Intervention: LTG 240 mg
Number of subjects: 0
Study 1773780 — intervention group
Group type: COMPARATOR
Intervention: LTG 120 mg
Number of subjects: 0
Study 1773780 — intervention group
Group type: COMPARATOR
Intervention: PHT 1,000 mg
Number of subjects: 0
Study 1773780 — intervention group
Group type: COMPARATOR
Intervention: DZP 10 mg
Number of subjects: 0
Study 1773780 — intervention group
Group type: EXPERIMENTAL
Intervention: LTG 150 mg
Number of subjects: 0
Study 1773780 — intervention group
Group type: COMPARATOR
Intervention: CBZ 600 mg
Number of subjects: 0
Study 1773780 — intervention group
Group type: COMPARATOR
Intervention: CBZ 400 mg
Number of subjects: 0
Study 1773780 — intervention group
Group type: COMPARATOR
Intervention: CBZ 200 mg
Number of subjects: 0
Study 7074648 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended field (EF) radiotherapy
Number of subjects: 460
Study 7074648 — intervention group
Group type: COMPARATOR
Intervention: Involved field (IF) radiotherapy
Number of subjects: 460
Study 30797014 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-sided tumours
Number of subjects: 5239
Study 30797014 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-sided tumours
Number of subjects: 5239
Study 30797014 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse tumours
Number of subjects: 5239
Study 30797014 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage II tumours
Number of subjects: 5239
Study 23893533 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (active medication)
Number of subjects: 46
Study 23893533 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 46
Study 27020901 — intervention group
Group type: EXPERIMENTAL
Intervention: GUI knobology control (GUIK+)
Number of subjects: 101
Study 27020901 — intervention group
Group type: COMPARATOR
Intervention: No GUI knobology control (GUIK-)
Number of subjects: 101
Study 27020901 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall accuracy for fluid detection
Number of subjects: 101
Study 27020901 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of test performance between groups (GUIK+ and GUIK-)
Number of subjects: 101
Study 25082214 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive normative message (majority physically active)
Number of subjects: 1200
Study 25082214 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative normative message (majority not physically active)
Number of subjects: 1200
Study 25082214 — intervention group
Group type: COMPARATOR
Intervention: Control group (no message)
Number of subjects: 1200
Study 22357745 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g/d HAM-RS2
Number of subjects: 33
Study 22357745 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g/d HAM-RS2
Number of subjects: 33
Study 22357745 — intervention group
Group type: COMPARATOR
Intervention: Control (0 g/d)
Number of subjects: 33
Study 22357745 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatments in women
Number of subjects: 33
Study 19887342 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral protocol (nurse-led intervention)
Number of subjects: 234
Study 19887342 — intervention group
Group type: COMPARATOR
Intervention: Symptom management guide (non-nurse coach intervention)
Number of subjects: 234
Study 17138642 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen patch 100 mg once daily
Number of subjects: 223
Study 17138642 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac gel 2-4 g three times daily
Number of subjects: 223
Study 16334075 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-directed seamless care service
Number of subjects: 253
Study 16334075 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 253
Study 12466943 — intervention group
Group type: COMPARATOR
Intervention: Cycling (C)
Number of subjects: 11
Study 12466943 — intervention group
Group type: EXPERIMENTAL
Intervention: Running (R)
Number of subjects: 11
Study 9689272 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anaesthesia (group PO)
Number of subjects: 60
Study 9689272 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-ketamine anaesthesia (group PK)
Number of subjects: 60
Study 9689272 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anaesthesia (group I)
Number of subjects: 60
Study 7735089 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced case management services
Number of subjects: 0
Study 7735089 — intervention group
Group type: COMPARATOR
Intervention: Standard methadone maintenance services
Number of subjects: 0
Study 2567431 — intervention group
Group type: COMPARATOR
Intervention: 10 mg of salbutamol nebuliser solution in 2 ml of saline
Number of subjects: 103
Study 2567431 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of salbutamol in 2 ml (0.5 mg) of preservative‐free ipratropium bromide
Number of subjects: 103
Study 2567431 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (salbutamol and ipratropium bromide)
Number of subjects: 103
Study 5800365 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoke with different filters
Number of subjects: 91
Study 5800365 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigar tobacco smoke
Number of subjects: 91
Study 31559532 — intervention group
Group type: EXPERIMENTAL
Intervention: sc IFN β‐1a 44 µg tiw
Number of subjects: 335
Study 31559532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 335
Study 31033747 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-guided online F-PST
Number of subjects: 150
Study 31033747 — intervention group
Group type: COMPARATOR
Intervention: Self-guided online F-PST
Number of subjects: 150
Study 31033747 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face F-PST
Number of subjects: 150
Study 28493891 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDSVAX® B/E vaccine
Number of subjects: 1584
Study 28493891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1584
Study 25227220 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion
Number of subjects: 21
Study 25227220 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 21
Study 22663196 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% PA etching→SE primer→SE adhesive (PA/SEp+a)
Number of subjects: 0
Study 22663196 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% PA etching→SE adhesive (PA/SEa)
Number of subjects: 0
Study 22663196 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step self-etching adhesive (SE)
Number of subjects: 0
Study 22663196 — intervention group
Group type: EXPERIMENTAL
Intervention: Etch-and-rinse adhesive (SB)
Number of subjects: 0
Study 22128728 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg dose of armodafinil
Number of subjects: 48
Study 19406737 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic bevacizumab (5 mg/kg)
Number of subjects: 16
Study 19406737 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride (control)
Number of subjects: 16
Study 16778338 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Measurement (HBPM)
Number of subjects: 438
Study 16778338 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory Blood Pressure Measurement (ABPM)
Number of subjects: 438
Study 15259284 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of estradiol valerate (E2V) plus 2.5 mg of medroxyprogesterone acetate (MPA)
Number of subjects: 393
Study 15259284 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg E2V + 5 mg MPA
Number of subjects: 393
Study 15259284 — intervention group
Group type: COMPARATOR
Intervention: 2 mg estradiol (E2) and 1 mg norethisterone acetate (NETA)
Number of subjects: 393
Study 15259284 — intervention group
Group type: EXPERIMENTAL
Intervention: E2V/MPA regimens after dose increase
Number of subjects: 393
Study 15259284 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower E2V dose
Number of subjects: 393
Study 15259284 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 393
Study 15559710 — intervention group
Group type: EXPERIMENTAL
Intervention: Team Awareness (psychosocial program)
Number of subjects: 587
Study 15559710 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational training
Number of subjects: 587
Study 15559710 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 587
Study 10914173 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued low-dose aspirin
Number of subjects: 50
Study 10914173 — intervention group
Group type: COMPARATOR
Intervention: Stopped low-dose aspirin
Number of subjects: 50
Study 7778544 — intervention group
Group type: EXPERIMENTAL
Intervention: High Lp(a) levels
Number of subjects: 2424
Study 7778544 — intervention group
Group type: COMPARATOR
Intervention: Intermittent claudication
Number of subjects: 2424
Study 2330888 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 0
Study 2330888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 386397 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimipramine
Number of subjects: 0
Study 386397 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 0
Study 31466745 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined radiotherapy and hyperthermia
Number of subjects: 23
Study 28193214 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPRI navigation program (based on two Nurse Navigators and a web portal)
Number of subjects: 0
Study 28193214 — intervention group
Group type: COMPARATOR
Intervention: Routine delivery of oral anticancer therapy
Number of subjects: 0
Study 28193214 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPRI navigation program
Number of subjects: 0
Study 25909473 — intervention group
Group type: EXPERIMENTAL
Intervention: Blueberry supplementation (2 cups of frozen blueberries daily for 6 weeks)
Number of subjects: 0
Study 25909473 — intervention group
Group type: EXPERIMENTAL
Intervention: Blueberry supplementation
Number of subjects: 0
Study 25909473 — intervention group
Group type: COMPARATOR
Intervention: Carrot juice drink (control group)
Number of subjects: 0
Study 25437150 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavior therapy (ICBT) for 12 weeks
Number of subjects: 81
Study 25437150 — intervention group
Group type: COMPARATOR
Intervention: Basic attention control condition
Number of subjects: 81
Study 25437150 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavior therapy (ICBT)
Number of subjects: 81
Study 22486272 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous platelet concentrate (APC) applied in test defects
Number of subjects: 25
Study 22486272 — intervention group
Group type: COMPARATOR
Intervention: Guided tissue regeneration (GTR) without APC in control defects
Number of subjects: 25
Study 19282762 — intervention group
Group type: EXPERIMENTAL
Intervention: I‐4L model
Number of subjects: 189
Study 19282762 — intervention group
Group type: EXPERIMENTAL
Intervention: TEM model
Number of subjects: 189
Study 17639992 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinmaitong capsule (XMT)
Number of subjects: 63
Study 17639992 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 63
Study 15646383 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine (CHX) mouthrinse
Number of subjects: 13
Study 15646383 — intervention group
Group type: COMPARATOR
Intervention: Control rinse
Number of subjects: 13
Study 12217068 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical manipulation
Number of subjects: 100
Study 12217068 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical manipulation with exercise
Number of subjects: 100
Study 12217068 — intervention group
Group type: COMPARATOR
Intervention: Cervical joint mobilisation
Number of subjects: 100
Study 9640153 — intervention group
Group type: EXPERIMENTAL
Intervention: Size 3 laryngeal mask
Number of subjects: 60
Study 9640153 — intervention group
Group type: COMPARATOR
Intervention: Size 4 laryngeal mask
Number of subjects: 60
Study 9640153 — intervention group
Group type: EXPERIMENTAL
Intervention: Size 4 laryngeal mask (males)
Number of subjects: 60
Study 9640153 — intervention group
Group type: COMPARATOR
Intervention: Size 5 laryngeal mask
Number of subjects: 60
Study 9640153 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of air to the minimum effective volume
Number of subjects: 60
Study 8179453 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern technology and contemporary medical practices for managing opportunistic infections in AIDS patients
Number of subjects: 0
Study 2530507 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (0.36 or 0.72 mg/kg bolus followed by 0.071 or 0.143 mg/kg/hr for 150 min)
Number of subjects: 0
Study 2530507 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion (5%)
Number of subjects: 0
Study 2530507 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (higher dose rate)
Number of subjects: 0
Study 30898374 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator training with decreased practice variability
Number of subjects: 93
Study 30898374 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater mean scores during practice
Number of subjects: 93
Study 28772186 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centred self-care educational intervention
Number of subjects: 256
Study 28772186 — intervention group
Group type: COMPARATOR
Intervention: Usual care (self-care resources only)
Number of subjects: 256
Study 26025368 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hygienic‐dietary written recommendations about diet, exercise, light exposure and sleep hygiene
Number of subjects: 273
Study 26025368 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 273
Study 23810027 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement intervention for prescribing antihypertensive medication
Number of subjects: 0
Study 21091792 — intervention group
Group type: EXPERIMENTAL
Intervention: Test implant with a 1.8 mm turned neck (T)
Number of subjects: 18
Study 21091792 — intervention group
Group type: COMPARATOR
Intervention: Control implant with a 2.8 mm turned neck (C)
Number of subjects: 18
Study 19742339 — intervention group
Group type: EXPERIMENTAL
Intervention: GORE-TEX Dual Mesh fixing into peritoneum during sigmoid-colostomy
Number of subjects: 60
Study 19742339 — intervention group
Group type: COMPARATOR
Intervention: Control group (papillary sigmoid-colostomy through rectus abdominis and peritoneum)
Number of subjects: 60
Study 17208639 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab for 1 year
Number of subjects: 5102
Study 17208639 — intervention group
Group type: COMPARATOR
Intervention: Observation alone (Control)
Number of subjects: 5102
Study 14871913 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels
Number of subjects: 930
Study 14871913 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP levels
Number of subjects: 930
Study 14871913 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP levels at or above the 90th percentile (10.6 mg/L)
Number of subjects: 930
Study 14871913 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP levels at or above the mean plus 2 SDs (16.8 mg/L)
Number of subjects: 930
Study 14871913 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP levels for smokers
Number of subjects: 930
Study 14871913 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP levels for non-smokers
Number of subjects: 930
Study 11798886 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole plus L‐T(4) 50 microgram/d (Group A)
Number of subjects: 60
Study 11798886 — intervention group
Group type: COMPARATOR
Intervention: Methimazole in small dose only (Group B)
Number of subjects: 60
Study 11798886 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole plus L‐T(4) 50 microgram/d (Group C)
Number of subjects: 60
Study 9931893 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (50.4 Gy) and 12 cycles of 5‐fluorouracil and medium‐dose folinic acid
Number of subjects: 206
Study 9931893 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (50.4 Gy) and 6 cycles of 5‐fluorouracil and medium‐dose folinic acid
Number of subjects: 206
Study 9931893 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 206
Study 7799828 — intervention group
Group type: EXPERIMENTAL
Intervention: Premarin cream (0.625 mg conjugated oestrogens per gram of cream)
Number of subjects: 54
Study 7799828 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 54
Study 7799828 — intervention group
Group type: EXPERIMENTAL
Intervention: Premarin cream
Number of subjects: 54
Study 2838151 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose dactinomycin (60 micrograms/kg, later reduced to 45 micrograms/kg)
Number of subjects: 5
Study 2838151 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose dactinomycin (45 micrograms/kg)
Number of subjects: 5
Study 2838151 — intervention group
Group type: EXPERIMENTAL
Intervention: Other hepatotoxic agents
Number of subjects: 5
Study 31712087 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG event‐related functional connectivity during processing of predictive stimuli in MDD patients
Number of subjects: 0
Study 31712087 — intervention group
Group type: COMPARATOR
Intervention: EEG event‐related functional connectivity during processing of predictive stimuli in control subjects
Number of subjects: 0
Study 31686184 — intervention group
Group type: EXPERIMENTAL
Intervention: Redon drain
Number of subjects: 88
Study 31686184 — intervention group
Group type: COMPARATOR
Intervention: Quadrain drain
Number of subjects: 88
Study 28398597 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozanimod (3 mg single dose, 2 mg/d multiple doses for 28 days)
Number of subjects: 88
Study 28398597 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozanimod (1 mg/d and 1.5 mg/d for 28 days)
Number of subjects: 88
Study 28398597 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozanimod (first dose)
Number of subjects: 88